Skip to main content

Table 1 Baseline demographic, laboratory and radiological characteristics of the study patients and controls

From: Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience

Variable

SRB+CTB

SRB

Supportive

p

Age (years)

49.5 ± 5.2

47.2 ± 4.6

46.6 ± 4.3

0.2

BMI k/m2

27.7 ± 0.9

26.8 ± 0.5

27 ± 1.3

0.03

AST IU/l

97.6 ± 26.5

68 ± 15

89.5 ± 28.4

0.005

ALT IU/l

65 ± 12.2

85 ± 17

73.8 ± 11.5

0.001

Albumin gm/dl

3.37 ± 0.32

3.6 ± 0.3

3.4 ± 0.3

0.09

T.Bilirubin mg/dl

2.03 ± 0.3

1.94 ± 0.9

2.2 ± 0.4

0.48

WBC cell/µl

3.7 ± 0.3

4.3 ± 0.4

3.6 ± 0.5

0.000

HB gm/dl

11.2 ± 0.8

11.6 ± 0.6

10.9 ± 0.5

0.02

Platelets cell/µl

91.3 ± 8.3

100 ± 7

94.2 ± 10.2

0.03

INR

1.35 ± 0.08

1.32 ± 0.3

1.4 ± 0.1

0.5

Creatinine mg/dl

1.2 ± 0.5

0.9 ± 0.4

1.1 ± 0.3

0.14

CTP

6.3 ± 0.3

6.7 ± 0.7

6.5 ± 0.2

0.07

MELD

13.7 ± 1.4

14.2 ± 1.6

14 ± 1.2

0.6

AFP ng/dl (mean ± SE)

6211 ± 929

3154 ± 345

2710 ± 581

0.000

No of focal lesions

2.5 ± 1.1

2.4 ± 0.3

2.4 ± 0.9

0.9

Size (cm)

10.5 ± 4.1

11.2 ± 6.3

8.7 ± 2.4

0.3

PVT (n)

11(73.3 %)

12 (75 %)

9 (60 %)

0. 8

Survival (months)

12.9 ± 2.1

7.9 ± 0.9

4.5 ± 1.3

0.000

  1. Italic values indicate significant differences when p < 0.05
  2. SRB sorafenib, CTB capcitabine, BMI body mass index, CTP child turcott pugh, MELD model for end stage liver disease, AFP alfafetoprotein